Colby Serpa💡

Merge fields, nature is the only industry. @NostrRelay @BiophillicLife

[Colby Serpa💡 @ColbySerpa]

Become addicted to the excitement of uncovering why you failed so that your curiosity grows as your effort does.

[Colby Serpa💡 @ColbySerpa]

Learning often requires curiosity to be stronger than cognitive dissonance, especially when unlearning.

[Jesse Morse, M.D. @DrJesseMorse]

BPC-157 ✅
TB-500 ✅
MOTS-c ✅
KPV ✅

4/4 peptides approved today 💪🏻

[Hims House @himshouse]

🚨 BREAKING: FDA PEPTIDE PANEL VOTES YES ON BPC-157

$HIMS

[Biophillic Research Institute @BiophillicLife]

Cellular senescence: a double-edged sword in cancer therapy ⚔️

SASP-inflammation is emitted from senescent cells to attract immune cells that will destroy the senescent cells.

When the immune system is exhausted (e.g. T cell exhaustion from mitochondrial weakening) and SASP fails to recruit the immune cells needed to eliminate senescence or cancer, then the dark side of SASP worsens due to persistent SASP harming neighboring normal cells.

Once a senescent cell is destroyed by a T cell or NK cells, the SASP it emits resolves — meaning persistent SASP may be a dysfunction of the immune system. ⬇️

“SASP can eliminate senescent cells or cancer cells by activating immune responses, persistent SASP signaling may promote tumorigenesis in neighboring normal cells, as well as EMT.”
https://t.co/JBslBmHfq2

[Biophillic Research Institute @BiophillicLife]

COVID-19 still claims more than 100,000 US lives each year🪦

"During the 2022–2023 period, there were an estimated 43.6 million COVID-19-associated illnesses, 10.0 million outpatient visits, 1.1 million hospitalizations, and 101,300 deaths.

During the 2023–2024 period, there were an estimated 33.0 million COVID-19-associated illnesses, 7.7 million outpatient visits, 879,100 hospitalizations, and 100,800 deaths.

Adults aged 65 years and older made up 17.7% of the total US population during 2023–2024 and accounted for 47.9% of COVID-19-associated illnesses. 65 and older accounted for 64.3% of COVID-19-associated outpatient visits, 67.6% of associated hospitalizations, and 81.2% of deaths."
https://t.co/7nk9adNTVd

[Colby Serpa💡 @ColbySerpa]

Currently, there are two arms... BRI and Helixer. BRI is non-profit research, studying molecules that Helixer does not patent. Helixer is for-profit, studying patented molecules that could be taken to trial.

These protocols mix peptides, small molecules, MUSE stem cells, and supplements in targeted ways. The goal is to achieve synergy between compounds while still maintaining normal BP, heart rate, and temperature, et al.

For example, the immune stack mitigates immune exhaustion by powering the mitochondria of immune cells while concurrently increasing the proliferation of immune cells.

Furthermore, the damaged or infected cells that are eliminated by T-cells/NK-cells/etc are scavenged through efferocytosis via M2 Macrophages.

M2 Macrophages are like Pac-men that digest apoptotic bodies, and are also involved in RCT during atherosclerosis regression. They are a fundamental component to many of our protocols.

We have been designing therapies that enhance every axis of this feedback loop for years. The immune stack was first born during the COVID era, while working at Peptide Sciences. We are now designing the cancer stack, senescence stack, atherosclerosis stack.

The autoimmune stack will need to wait until later given it is the most experimental, requiring the wiping of memory B cells and the retraining of them... there are many prerequisites required before we can safely retrain memory B cells after wiping them.

Happy to explain more on a call. This has been many years in the making, and this is a coming out moment. I tried to go toward the non-profit angle for as long as I could, but I don't see it as realistic anymore. It's too difficult to raise funds without a profit incentive. I'm friends with @NiklasAnzinger from Prospera as well and visited 2 years ago. We are planning to do legal Phase 1 trials there after our mouse trials at the @LifespanRI.

We already have a relationship with the LRI and have an agreement to conduct mouse trials there.

[Colby Serpa💡 @ColbySerpa]

@ChrisWillx @naval good one

[🌸JL🌸 @na_la_la]

Cosmically, wood is more rare than diamonds.

[Based ₿en @based_benji]

They replaced apprenticeship with debt and call it progress.

[Colby Serpa💡 @ColbySerpa]

https://t.co/36rsJO6YGb

[Adam Shuaib @adamshuaib]

Ultra successful people often started their career working on embarrassing projects; a problem space others thought was a waste of time or too low-status.

Darwin spent 8yrs studying barnacle taxonomy. When the Wright Brothers started working on human flight, scientists considered it an idiot's pursuit after decades of failures. Steve Jobs took calligraphy classes that ultimately inspired the first Mac.

Ambitious people tend to work on respectable problems that show how smart they are. But most truly important questions usually look dumb before they look obvious, and the fear of appearing stupid keeps most people competing for the same set of obvious opportunities

The prestigious problem has 100 people on it, and the embarrasing one does not because everyone was too proud to be seen there. Only one of them ends up changing the world.

[Colby Serpa💡 @ColbySerpa]

https://t.co/Tp4EW3z1y4

[𓂀 𝕋𝕙𝕖 ℂ𝕦𝕣𝕒𝕥𝕠𝕣 𓂀 @psyhiris]

Lighthouse

[Edward Hopper @artisthopper]

Lighthouse Hill (1927) sets a stark white lighthouse above a shadowed cottage on a grassy rise. The vertical beacon cuts through shifting clouds and wind. Its certainty contrasts with the house’s dark façade, symbolizing artificial guidance standing firm amid... #artbots #hopper

[The Redheaded libertarian @TRHLofficial]

“The world only makes sense if you force it to.”

[@jackbutcher @jackbutcher]

"Still Going"

Tomorrow.

networked dot art

[Nick Szabo @NickSzabo4]

Trusted third parties are security holes. Whether the strangers in question are or are portrayed as "good guys" or "bad guys" does not make much difference, they are still security risks.

[Paul Graham @paulg]

A startup doesn't have to be your life's work, but if it is, you become much harder to defeat. You play the long game and you outlast everyone. Because practically everyone else is an opportunist by comparison.